[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A, Tomita K: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res; 2005 May-Jun;25(3c):2399-405
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue.
  • BACKGROUND: We previously reported that caffeine-potentiated chemotherapy induced significantly good response in patients with musculoskeletal sarcomas.
  • In that series, patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • PATIENTS AND METHODS: Five patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • RESULTS: Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer.
  • Good responses (gross tumor shrinkage >30%, or histologically >90% necrosis) to chemotherapy were seen in all five patients.
  • Survival time was >1 year in all patients, and three out of five patients presented no evidence of local recurrence or metastasis at the final follow-up.
  • CONCLUSION: Caffeine-potentiated chemotherapy may be of benefit for malignant tumors other than musculoskeletal sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Caffeine / pharmacology. Carcinoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080466.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


2. Dasanu CA, Herzog TJ: Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview. Medscape J Med; 2009;11(1):6
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview.
  • BACKGROUND: Clear cell adenocarcinoma of the vagina and cervix were previously shown to be tumors occurring in female offspring exposed prenatally to diethylstilbestrol.
  • This report describes the first clinical case of clear cell adenocarcinoma of the ovary linked to early diethylstilbestrol exposure in utero.
  • She underwent surgery and staging that revealed clear cell adenocarcinoma confined to the left ovary.
  • Medical records established unequivocally that the patient's mother received diethylstilbestrol therapy throughout the pregnancy.
  • CONCLUSION: Our case is consistent with clear cell adenocarcinoma, probably related to diethylstilbestrol exposure in utero.
  • It reinforces the need for continued vigilance in individuals prenatally exposed to this drug.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemically induced. Diethylstilbestrol / adverse effects. Ovarian Neoplasms / chemically induced. Prenatal Exposure Delayed Effects / chemically induced

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):837-45 [11714112.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1615-24 [7370920.001]
  • [Cites] Biol Reprod. 1983 Apr;28(3):735-44 [6850046.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):85-96 [2469661.001]
  • [Cites] Epidemiology. 2008 Mar;19(2):251-7 [18223485.001]
  • [Cites] Semin Diagn Pathol. 1997 Nov;14(4):233-9 [9383823.001]
  • [Cites] Obstet Gynecol. 2005 Jan;105(1):167-73 [15625159.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):356-60 [17390375.001]
  • [Cites] Semin Surg Oncol. 1990;6(6):343-6 [2263810.001]
  • (PMID = 19295927.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  • [Other-IDs] NLM/ PMC2654676
  •  go-up   go-down


3. Hentati D, Belghith B, Kochbati L, Driss M, Maalej M: Clear cell carcinoma of the uterus. Tunis Med; 2010 Apr;88(4):230-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the uterus.
  • AIM: The aim of this study was to determine the characteristics and outcome of patients presenting with clear cell carcinoma (CCC) of the endometrium treated in a single institution.
  • The mean age at diagnosis was 64 years (50 to 84 yers).
  • After a median follw up of 32 months, 4 patients presented with recurrences: one vaginal recurrence, two cases of pelvic and abdominal recurrence and abdominal recurrence in one patient.
  • Two patients with abdomino-pelvic recurrences progressed despite the association of surgery, radiation therapy and chemotherapy.
  • CONCLUSION: Extrauterine extension is frequent at diagnosis and not correlated to classical risk factors observed in endometrioid carcinoma.
  • A comptlete surgical staging is necessary for adjuvant treatment.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446254.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


Advertisement
4. Laitman CJ: DES exposure and the aging woman: mothers and daughters. Curr Womens Health Rep; 2002 Oct;2(5):390-3
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DES exposure and the aging woman: mothers and daughters.
  • Diethylstilbestrol (DES), the first orally active artificial estrogen ever developed, was prescribed to several million pregnant women during the 1940s through the 1960s in the mistaken belief that it reduced the risk of miscarriage.
  • In 1971, the US Food and Drug Administration contraindicated its use in pregnancy when DES was associated with the development of vaginal clear cell adenocarcinoma (CCA) in daughters exposed in utero.
  • In daughters whose mothers took DES during pregnancy, the drug has been associated with congenital malformations of the reproductive tract, fertility problems, a possible increased risk of cervical carcinoma in situ, and a presumed lifetime risk of vaginal and cervical CCA.
  • DES mothers have an increased risk of breast cancer (RR = 1.3).
  • DES sons have an increased prevalence of urogenital anomalies, and a possible increased risk of testicular cancer.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Breast Neoplasms / chemically induced. Carcinoma in Situ / chemically induced. Estrogen Replacement Therapy. Female. Genitalia, Female / abnormalities. Humans. Mothers. Nuclear Family. Pregnancy. Pregnancy Complications / prevention & control. Pregnancy, High-Risk. Risk Factors. Uterine Cervical Neoplasms / chemically induced. Vaginal Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12215312.001).
  • [ISSN] 1534-5874
  • [Journal-full-title] Current women's health reports
  • [ISO-abbreviation] Curr Womens Health Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


5. Swan SH: Intrauterine exposure to diethylstilbestrol: long-term effects in humans. APMIS; 2000 Dec;108(12):793-804
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DES is the most carefully scrutinized EDC and its history provides valuable insights into the current evaluation of less well-studied EDCs.
  • This review summarizes the health effects of prenatal exposure to diethylstilbestrol (DES) and emphasizes the role of DES as the first endocrine disrupting chemical (EDC).
  • Vaginal clear cell adenocarcinoma (CCAC), the most severe consequence of prenatal exposure to DES, affected only 0.1% of exposed females, while the far more prevalent teratogenic and reproductive effects of DES were only discovered when DES daughter were screened for CCAC.
  • Initial studies, conducted before most DES daughters had tried to conceive, examined vaginal cancer and vaginal, cervical and uterine abnormalities.
  • Subsequently, several controlled studies demonstrated the increased risk of adverse reproductive outcomes in DES daughters.
  • While most DES daughters can eventually experience a live birth, this is less likely in women with genital tract abnormalities, in whom there is a two-thirds chance that each pregnancy will be unsuccessful.
  • In DES sons, who have been far less studied, results suggest male reproductive toxicity, but are less consistent.
  • The importance of dose and gestational age at initial exposure are discussed, and the implications of DES findings for the evaluation of risks from current EDCs emphasized.
  • [MeSH-major] Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Pregnancy Complications / drug therapy. Prenatal Exposure Delayed Effects
  • [MeSH-minor] Abnormalities, Drug-Induced / epidemiology. Adenocarcinoma, Clear Cell / chemically induced. Administration, Intravaginal. Cervix Uteri / abnormalities. Female. Follow-Up Studies. Gestational Age. Humans. Infant, Newborn. Infant, Newborn, Diseases / chemically induced. Infant, Newborn, Diseases / epidemiology. Male. Pregnancy. Risk. Teratoma / chemically induced. Testicular Neoplasms / chemically induced. United States / epidemiology. Uterus / abnormalities. Vagina / abnormalities. Vaginal Diseases / chemically induced. Vaginal Diseases / epidemiology. Vaginal Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11252812.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  • [Number-of-references] 75
  •  go-up   go-down


6. Mahdavi A, Shamshirsaz AA, Peiretti M, Zakashansky K, Idrees MT, Nezhat F: Laparoscopic management of vaginal clear cell adenocarcinoma arising in pelvic endometriosis: case report and literature review. J Minim Invasive Gynecol; 2006 May-Jun;13(3):237-41
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of vaginal clear cell adenocarcinoma arising in pelvic endometriosis: case report and literature review.
  • Vaginal clear cell adenocarcinoma arising from pelvic endometriosis has not been reported in the literature.
  • We report a case of a 50-year-old woman with stage I clear cell adenocarcinoma of the vagina who was found to have endometriosis adjacent to the vaginal tumor.
  • She was treated with neoadjuvant chemoradiation, laparoscopically assisted radical vaginal hysterectomy, radical upper vaginectomy, and pelvic lymphadenectomy followed by combination chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Endometriosis / complications. Endometriosis / surgery. Vaginal Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Humans. Laparoscopy. Middle Aged. Neoplasm Staging. Pelvis

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698533.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


7. Koizumi T, Bando S, Kanda K, Inai T: [Two cases of primary female urethral cancer]. Nihon Hinyokika Gakkai Zasshi; 2007 Sep;98(6):790-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of primary female urethral cancer].
  • Herein, we report two cases of female urethral cancer.
  • Histopathological examination of transperineal biopsy specimens from both patients suggested clear cell adenocarcinoma in case 1 and squamous cell carcinoma in case 2.
  • Both cases underwent total urethrectomy with partial resection of the vaginal wall and cystostomy urinary diversion.
  • With reference to case 1, obturator lymph node metastases were observed during surgery, and treatment comprised combined radiotherapy to 60 Gy and chemotherapy with 5-fluorouracil and cisplatin following surgery.
  • However, metastases appeared in the lung 6 months after initial treatment and she died 20 months after surgery.
  • The same combined treatment was performed and a complete response was obtained.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urethral Neoplasms / drug therapy. Urethral Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Urethral cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929463.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


8. Gangopadhyay M, Raha K, Sinha SK, De A, Bera P, Pati S: Endodermal sinus tumor of the vagina in children: a report of two cases. Indian J Pathol Microbiol; 2009 Jul-Sep;52(3):403-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endodermal sinus tumor of the vagina in children: a report of two cases.
  • Malignant tumors of the vagina in infants and children are rare, with primary germ cell tumor (endodermal sinus tumor [EST]) being rarer, which carries a dismal prognosis.
  • This tumor is often clinically mistaken as botryoid rhabdomyosarcoma and, on histopathological examination, is often misdiagnosed as clear cell adenocarcinoma.
  • Two cases of EST of the vagina in infants aged 9 and 17 months are reported.
  • Both the patients presented with bleeding per vagina and clinically and by ultrasonography were diagnosed as sarcoma botryoides.
  • One patient aged 9 months expired 2 months after receiving chemotherapy.
  • The other, aged 17 months, was given chemotherapy followed by surgery with reduction of the AFP levels.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / pathology. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Female. Hemorrhage / etiology. Histocytochemistry. Humans. Infant. Treatment Outcome. Vagina / pathology. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679975.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


9. Nagarsheth NP, Harrison M, Kalir T, Rahaman J: Malignant pericardial effusion with cardiac tamponade in a patient with metastatic vaginal adenocarcinoma. Int J Gynecol Cancer; 2006 May-Jun;16(3):1458-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pericardial effusion with cardiac tamponade in a patient with metastatic vaginal adenocarcinoma.
  • Malignant pericardial effusion with cardiac tamponade is a rare manifestation of metastatic gynecological cancer.
  • A 35-year-old female was diagnosed with clear cell adenocarcinoma of the vagina.
  • Four years after partial vaginectomy, she developed regional recurrence and was treated with surgical excision followed by platinum-based chemotherapy and radiation therapy.
  • Six years later, the patient was diagnosed with lung metastases and received a combination adriamycin and platinum-based chemotherapy.
  • Shortly after completing treatment, she presented with weakness and was found to be hypotensive on physical exam.
  • Computed tomography scan confirmed a pericardial effusion with evidence of bilateral heart failure.
  • She underwent an emergent pericardiocentesis and eventual pericardial window procedure.
  • Metastatic adenocarcinoma of the vagina can present with malignant pericardial effusion with cardiac tamponade.
  • Therefore, gynecologists and gynecological oncologists need to be familiar with the diagnosis and management of this disease process.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Cardiac Tamponade / etiology. Pericardial Effusion / etiology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Heart Neoplasms / diagnosis. Heart Neoplasms / secondary. Humans. Pericardiocentesis / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803549.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


10. Fujiwara K, Suzuki S, Yoden E, Ishikawa H, Imajo Y, Kohno I: Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy. Int J Gynecol Cancer; 2002 May-Jun;12(3):250-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.
  • The purpose of this paper is to prospectively evaluate the effects of local radiation therapy upon localized ovarian cancer following chemotherapy.
  • Patients with objective relapses or refractory disease but with localized epithelial ovarian cancers and who had undergone at least one regimen of chemotherapy were enrolled in this study.
  • The interval between previous chemotherapy and radiation therapy was 4.5 months.
  • The irradiation dose was 52.3 +/- 8.3 Gy.
  • Forty-four disease sites, including the lymph nodes, vaginal cuff, pelvis, abdomen, subcutaneous regions, and the brain were irradiated.
  • Regression rates correlated with longer survivals (P = 0.0195) after radiation therapy.
  • Survival was significantly better when radiation therapy was given before patients had symptoms (P = 0.001).
  • We conclude that local radiation therapy may be one of the treatment options for relapsed or refractory but localized ovarian cancer, particularly when the tumor is small and/or located in the lymph nodes, even when patients had no symptoms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Neoplasm Recurrence, Local / radiotherapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiotherapy. Adult. Aged. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma / radiotherapy. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radiotherapy. Combined Modality Therapy. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radiotherapy. Female. Humans. Middle Aged. Neoplasm Staging. Neoplasms, Glandular and Epithelial / drug therapy. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / radiotherapy. Pilot Projects. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060445.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP: Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1145-53
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy.
  • OBJECTIVE: To evaluate the risk of pelvic recurrence (PVR) in high-risk pathologic Stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone.
  • METHODS: Between 1992 and 1998, 43 high-risk endometrial cancer patients received adjuvant chemotherapy.
  • No patients received preoperative radiation therapy (RT).
  • All patients received 4-6 cycles of chemotherapy as the sole adjuvant therapy, consisting primarily of cisplatin and doxorubicin.
  • Recurrent disease sites were divided into pelvic (vaginal, nonvaginal) and extrapelvic (para-aortic, upper abdomen, liver, and extra-abdominal).
  • Of the 17 women who developed a PVR, 8 relapsed in the vagina, 3 in the nonvaginal pelvis, and 6 in both.
  • The 3-year vaginal and nonvaginal PVR rates were 37.8% and 26%, respectively.
  • The most significant factor correlated with vaginal PVR was CI (p = 0.0007).
  • Nine of the 29 relapsed patients (31%) developed PVR as their only (6) or first site (3) of recurrence.
  • CONCLUSIONS: PVR is common in high-risk pathologic Stage I-IV endometrial cancer patients after adjuvant chemotherapy alone.
  • These results support the continued use of locoregional RT in patients undergoing adjuvant chemotherapy.
  • Further studies are needed to test the addition of chemotherapy to locoregional RT.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Endometrial Neoplasms / drug therapy. Pelvic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / prevention & control. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / therapy. Adult. Aged. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / therapy. Chicago / epidemiology. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma, Papillary / epidemiology. Cystadenocarcinoma, Papillary / prevention & control. Cystadenocarcinoma, Papillary / secondary. Cystadenocarcinoma, Papillary / therapy. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Ovariectomy. Radiotherapy, Adjuvant. Retrospective Studies. Risk. Treatment Outcome. Vaginal Neoplasms / epidemiology. Vaginal Neoplasms / prevention & control. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483323.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Novoa Vargas A, Grados García C, Bustillos de Cima R, Malagón Millán B: [Vagina cancer in a young woman exposed to diethylstilbestrol: case report and literature review]. Ginecol Obstet Mex; 2005 Dec;73(12):666-73
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vagina cancer in a young woman exposed to diethylstilbestrol: case report and literature review].
  • [Transliterated title] Cáncer de vagina en una mujer joven expuesta a dietilestilbestrol: caso clínico y revisión de la bibliografía.
  • We analyzed a 20 year-old patient case exposed in utero to diethylstilbestrol, as probably predisposed factor in vaginal cancer.
  • The histopathological report of the incisional biopsy was clear cell vaginal adenocarcinoma, stage III, widespread to the pelvic wall, with metastasis to regional lymph nodes, and lack of distant metastasis.
  • We decided surgical management: protocolized laparotomy, peritoneal washing, retroperitoneal node biopsies and a radical hysterectomy, Piver III, with two thirds parts of vagina.
  • By poor prognosis we decided to offer an adjuvant management, with systemic chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemically induced. Diethylstilbestrol / adverse effects. Prenatal Exposure Delayed Effects. Vaginal Neoplasms / chemically induced
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy. Lymphatic Metastasis. Pregnancy. Prognosis. Radiography, Abdominal. Time Factors. Tomography, X-Ray Computed. Vagina / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583845.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


13. Seki H, Takada T, Sodemoto T, Hoshino H, Saitoh K, Uekusa T: A young woman with clear cell adenocarcinoma of the uterine cervix. Int J Clin Oncol; 2003 Dec;8(6):399-404
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A young woman with clear cell adenocarcinoma of the uterine cervix.
  • In May 1999, an 18-year-old woman visited a physician because of vaginal bleeding and the excretion of large clots from the vagina.
  • A vaginal tumor was discovered and the patient was referred to our outpatient department.
  • Vaginal examination showed a bleeding, tumor, approximately 6 cm in size, protruding from the cervical os and filling the vagina.
  • The cytological finding of the uterine cervix was class V, and the histological diagnosis by punch biopsy was clear cell adenocarcinoma (CCAC) of the uterine cervix.
  • The patient initially received neoadjuvant chemotherapy (NAC) with intraarterial injections of 8 mg/m(2) of mitomycin, 270 mg/m(2) of etoposide, and 380 mg/m(2) of carboplatin.
  • Pathological diagnosis was CCAC of the cervix (pT2a, N0, M0).
  • The patient was discharged from our hospital without any postoperative chemotherapy or radiation therapy.
  • While there were similarities between the patients in the two countries in the patients' pattern of growth and the poor prognosis of the tumors, there was a significant difference between the countries in the patients' history of diethylstilbestrol (DES) exposure.
  • These results suggest that menarche and menopause may play roles in promoting carcinogenesis, or alternatively, that a subpopulation of women are subject to genetic or exogenous risk factors other than DES.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adolescent. Age of Onset. Carboplatin / administration & dosage. Carcinogens / adverse effects. Diethylstilbestrol / adverse effects. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Japan. Lymph Node Excision. Mitomycin / administration & dosage. Neoadjuvant Therapy. Netherlands. Prognosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Clin Oncol. 2004 Jun;9(3):213; author reply 213-4 [15221610.001]
  • (PMID = 14663645.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinogens; 50SG953SK6 / Mitomycin; 6PLQ3CP4P3 / Etoposide; 731DCA35BT / Diethylstilbestrol; BG3F62OND5 / Carboplatin
  •  go-up   go-down


14. Yokoyama Y, Sakamoto A, Umemoto M, Futagami M, Sakamoto T, Maruyama H, Sato S, Mizunuma H: A case of adenocarcinoma of the endometrial type mixed with a clear cell component that metastasized to the vagina. Eur J Gynaecol Oncol; 2003;24(5):435-7
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of adenocarcinoma of the endometrial type mixed with a clear cell component that metastasized to the vagina.
  • We present a patient with adenocarcinoma of the endometrial type mixed with a clear cell component (AMC) that metastasized to the vagina and one of the pelvic lymph nodes.
  • She underwent a radical hysterectomy and pelvic and paraaortic lymphadenectomy, and then received postoperative adjuvant chemotherapy.
  • Histologic features of the endometrial tumor included clear cell adenocarcinoma with an approximate 10% extent to endometrioid adenocarcinoma.
  • On the other hand, histologic examination on the vaginal tumor predominatly showed clear cell adenocarcinoma and also revealed endometrioid adenocarcinoma to a very small extent, suggesting metastasis to the vagina from AMC.
  • On immunohistochemical examination, expression of vascular endothelial growth factor (VEGF)-A, VEGF-C and VEGF-D was apparently stronger in the component of clear cell adenocarcinoma than in that of endometrioid adenocarcinoma.
  • Interestingly, locations of endometrial and vaginal lesions were consistent with the sites of an intrauterine device and ring pessary insertion, respectively.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Endometrial Neoplasms / pathology. Vaginal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14584665.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Guiou M, Hall WH, Konia T, Scudder S, Leiserowitz G, Ryu JK: Primary clear cell adenocarcinoma of the rectovaginal septum treated with concurrent chemoradiation therapy: a case report. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1118-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the rectovaginal septum treated with concurrent chemoradiation therapy: a case report.
  • Primary clear cell adenocarcinoma of the rectovaginal septum is rare and typically emerges in the setting of endometriosis.
  • We report a case of a 52-year-old woman with clear cell adenocarcinoma of the rectovaginal septum presenting with vaginal hemorrhage.
  • Six years following the completion of treatment, the patient is without evidence of disease or significant long-term toxicity.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / radiotherapy. Antineoplastic Agents / therapeutic use. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986241.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Tan YT, Zhang X, Lin ZQ, Chen Q, Wang LJ, Zhang BZ: [Primary clear cell carcinoma of the cervix: report of five cases and review of the literature]. Zhonghua Fu Chan Ke Za Zhi; 2008 Feb;43(2):120-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary clear cell carcinoma of the cervix: report of five cases and review of the literature].
  • OBJECTIVE: To explore the clinical diagnostic and therapeutic characteristics, prognostic factors of patients with primary clear cell carcinoma of the cervix.
  • METHODS: The clinical, pathologic and follow-up data of patients with primary clear cell carcinoma of the cervix treated in our hospital from Jan 2003 to Dec 2006 were collected and analyzed retrospectively.
  • RESULTS: Five patients with primary clear cell carcinoma of the cervix were treated (1 case stage I b1, 2 of stage I b2, 1 of stage IIa, 1 of stage IVa).
  • The primary symptom was mostly irregularly vaginal bleeding (3/5) and clinical type was predominantly (4/5) endophytic growth.
  • All of four patients underwent four courses of chemotherapy with fluorouracil (5-FU) and carboplatin, one patient (stage II a) was added with intracavitary brachytherapy.
  • Pelvic relapse occurred three months after operation and the patient then underwent the second operation, external beam radiotherapy and intracavitary brachytherapy and 8 courses of chemotherapy with paclitaxel (taxol) and carboplatin.
  • CONCLUSIONS: Primary clear cell carcinoma of the cervix may be unrelated to HPV infection.
  • Operation combined with chemotherapy with carboplatin and 5-FU or taxol may lead to relatively perfect short-term therapeutical effect.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. CA-125 Antigen / blood. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cervix Uteri / pathology. Female. Fluorouracil / administration & dosage. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Retrospective Studies


17. Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley H, Lee RB, Gehrig PA, Zaino R: Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol; 2006 Feb;100(2):349-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group.
  • OBJECTIVES: To evaluate outcome in patients with clinical stage I/II papillary serous (PS) or clear cell (CC) endometrial carcinoma treated with whole abdominal radiotherapy.
  • RESULTS: Among 21 PS patients (median age: 68 years), one refused therapy, and another received a non-protocol vaginal boost.
  • Five others died due to protocol treatment (1), toxicity from subsequent chemotherapy (1), intercurrent disease (1), and unknown cause (2).
  • Among treated patients who DOD, sites of recurrence included lung (2), lung/vagina (1), abdomen/pelvis (1), vagina (1), and abdomen (2).
  • Among patients who DOD, sites of recurrence included lung (1), vagina (1), and unknown (1).
  • CONCLUSIONS: Over half of the treatment failures were within the radiation field.
  • Systemic chemotherapy, radiosensitizing chemotherapy, or sequential radiation and chemotherapy should be considered in future adjuvant trials for these patients.
  • [MeSH-major] Adenocarcinoma, Clear Cell / radiotherapy. Carcinoma, Papillary / radiotherapy. Cystadenocarcinoma, Serous / radiotherapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Ovariectomy. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213007.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 12477; United States / NCI NIH HHS / CA / CA 12482; United States / NCI NIH HHS / CA / CA 12484; United States / NCI NIH HHS / CA / CA 12534; United States / NCI NIH HHS / CA / CA 13630; United States / NCI NIH HHS / CA / CA 13633; United States / NCI NIH HHS / CA / CA 15975; United States / NCI NIH HHS / CA / CA 16386; United States / NCI NIH HHS / CA / CA 16938; United States / NCI NIH HHS / CA / CA 21720; United States / NCI NIH HHS / CA / CA 21946; United States / NCI NIH HHS / CA / CA 23073; United States / NCI NIH HHS / CA / CA 23501; United States / NCI NIH HHS / CA / CA 23765; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 28160; United States / NCI NIH HHS / CA / CA 34477; United States / NCI NIH HHS / CA / CA 35640; United States / NCI NIH HHS / CA / CA 37535; United States / NCI NIH HHS / CA / CA 37569; United States / NCI NIH HHS / CA / CA 40296
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


18. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1272-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
  • PURPOSE: To evaluate the outcome and patterns of failure in women with uterine clear-cell carcinoma and discuss implications for adjuvant radiation therapy (RT).
  • Thirty-eight women (5.5%) had clear-cell tumors (18 clear-cell only, 8 clear-cell + adenocarcinoma, and 12 clear-cell + other unfavorable histologies [10 papillary serous, 1 uterine sarcoma, 1 both]).
  • Adjuvant therapies included the following: 5 none, 22 RT (13 pelvic RT, 2 vaginal brachytherapy, 7 both), 11 chemotherapy (8 alone, 3 after pelvic RT), and 3 hormones.
  • Patients with clear +/- adenocarcinoma histology had a similar 5-year disease-free survival (38.8% vs. 38.7%, p = 0.95) compared with those with clear-cell + other unfavorable histologies.
  • Eight failed in the pelvis (5 vagina, 3 lateral pelvis).
  • Only 1 (2%) patient developed an isolated abdominal failure (This patient had a mixed clear-cell/papillary serous tumor).
  • Of the 26 women with clear-cell +/- adenocarcinoma histology, only 1 (3.8%) relapsed in the abdomen.
  • CONCLUSION: Clear-cell carcinoma comprises a small percentage of endometrial cancers, frequently presents as a mixed histology, and has a poor overall outcome.
  • Unlike papillary serous tumors, clear-cell carcinoma does not seem to have a high propensity for abdominal failure.
  • Future protocols should focus instead on combinations of locoregional RT and chemotherapy to reduce the risk of local and systemic recurrence.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Radiotherapy, Adjuvant
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brachytherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Pelvic Neoplasms / secondary. Prognosis. Sarcoma / pathology. Treatment Failure. Treatment Outcome. Uterine Neoplasms / pathology. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654437.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 30
  •  go-up   go-down


19. Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP: Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1154-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma.
  • OBJECTIVE: To determine the outcome, pattern(s) of failure, and optimal treatment volume in Stage IIIC endometrial carcinoma patients treated with surgery and postoperative radiation therapy (RT).
  • Adjuvant vaginal brachytherapy (VB) was delivered in 10, chemotherapy in 5, and hormonal therapy in 7 patients.
  • Of the 7 pelvic failures, 4 were vaginal (3 vaginal only).
  • Patients treated with VB had a trend to a lower vaginal recurrence rate (0/10 vs. 4/20, p = 0.12) than those not receiving VB.
  • No patient developed an isolated abdominal recurrence.
  • Two patients developed significant RT sequelae: chronic diarrhea in 1 patient treated with WPRT and VB, and small bowel obstruction in 1 patient treated with EFRT.
  • Given the predominance of failure in distant sites, attention should be focused on the development of systemic chemotherapy protocols.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy. Hysterectomy. Ovariectomy. Radiotherapy, Adjuvant
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Chicago / epidemiology. Combined Modality Therapy. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / radiotherapy. Cystadenocarcinoma, Papillary / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Life Tables. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483324.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


20. Pinto AB, Gopal M, Herzog TJ, Pfeifer JD, Williams DB: Successful in vitro fertilization pregnancy after conservative management of endometrial cancer. Fertil Steril; 2001 Oct;76(4):826-9
MedlinePlus Health Information. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful in vitro fertilization pregnancy after conservative management of endometrial cancer.
  • OBJECTIVE: To report a successful IVF pregnancy in an infertile couple after conservative treatment of endometrial cancer.
  • MAIN OUTCOME MEASURE(S): Successful pregnancy after conservative management of endometrial cancer.
  • INTERVENTION(S): Grade 1 endometrial adenocarcinoma diagnosed at hysteroscopy, followed by dilatation and curettage (D&C).
  • On follow-up D&C, pathologic examination was normal after high-dose progesterone therapy.
  • Laparoscopic-assisted vaginal hysterectomy and bilateral salpingo-oophorectomy was then done.
  • No residual endometrial cancer was evident in the hysterectomy specimen, but a 1.1-cm cystic mixed endometrioid and clear cell-type adenocarcinoma was discovered in the left ovary.
  • The patient is doing well after 3 cycles of chemotherapy; her CA-125 level is normal.
  • CONCLUSION(S): In carefully chosen situations, deferring surgery in infertile patients with endometrial cancer may be a viable option permitting subsequent successful pregnancy.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy. Fertilization in Vitro. Pregnancy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Hysterectomy, Vaginal. Neoplasms, Second Primary / drug therapy. Ovarian Neoplasms / drug therapy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11591422.001).
  • [ISSN] 0015-0282
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Siow TR, Yeo MC, Khoo-Tan HS, Yap SP, Soong YL, Chua EJ, Soh LT, Lim YK, Chia YN, Yam KL: Stage 1C grade 3 endometrial cancer: the KK Hospital gynaecological oncology group experience. Int J Gynecol Cancer; 2010 Dec;20(9):1557-62
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage 1C grade 3 endometrial cancer: the KK Hospital gynaecological oncology group experience.
  • OBJECTIVE: It is our standard of care to include pelvic lymph node dissection (PLND) in the staging of endometrial cancer, followed by adjuvant vaginal vault brachytherapy.
  • We report our experience and outcome of patients with stage 1C grade 3 endometrial cancer from KK Hospital Singapore.
  • METHODS: Records of patients with a diagnosis of stage 1C grade 3 endometrial cancer (based on the 1988 FIGO [International Federation of Gynecology and Obstetrics] staging system) from 1995 to 2008 were retrospectively reviewed.
  • Details of surgery, chemotherapy, and radiotherapy were recorded, as were prognostic factors such as histological subtype and number of lymph nodes removed.
  • RESULTS: A total of 31 cases were reviewed; 29 had sufficient records to be analyzed, of which one was excluded as she had a second primary cancer (breast).
  • All but 1 case received postoperative vaginal vault brachytherapy.
  • Eight of 10 patients with nonendometrioid adenocarcinoma (eg, clear cell) histology also received adjuvant chemotherapy.
  • CONCLUSION: Pelvic lymph node dissection and vaginal vault brachytherapy seem to be effective in preventing locoregional recurrences, with few associated adverse effects.
  • Adjuvant chemotherapy should also be considered for cases with poor prognostic factors.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Algorithms. Brachytherapy. Combined Modality Therapy. Female. Gynecology / organization & administration. Hospitals. Humans. Hysterectomy. Lymphatic Metastasis. Medical Oncology / organization & administration. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Singapore. Societies, Medical. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119369.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Hogberg T, Fredstorp-Lidebring M, Alm P, Baldetorp B, Larsson G, Ottosen C, Svanberg L, Lindahl B, Southern Swedish Gynecologic Oncology Group: A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology. Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer. Int J Gynecol Cancer; 2004 May-Jun;14(3):437-50
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology. Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer.
  • A management program for FIGO stage I-II nonserous, nonclear-cell adenocarcinomas was evaluated.
  • Histopathology and DNA ploidy were used to estimate postoperatively the risk of progression or death of disease and to tailor treatment.
  • The patient material was a population-based consecutive cohort of all women with endometrial cancer in the Southern Swedish Health Care Region diagnosed between June 1993 and June 1996 (n = 553).
  • Patients estimated to be at low risk were treated by surgery only, while high-risk patients also received vaginal brachytherapy.
  • Although there is a clear indication for adjuvant therapy for this group, locoregional radiotherapy could be expected to fail in cases with distant progression.
  • Thus, effective systemic treatments need to be developed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Ploidies. Prospective Studies. Radiotherapy, Adjuvant. Registries. Risk Factors. Survival Analysis. Sweden / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15228416.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down






Advertisement